Cerebral Organoids Provide New Strategy to Personalize Glioblastoma Treatment

On this episode of Advances in Care, Erin Welsh speaks with Dr. Howard Fine, neuro-oncologist at NewYork-Presbyterian and director of the Brain Tumor Center at Weill Cornell Medicine, about his groundbreaking research in glioblastoma. Dr. Fine’s lab is bioengineering cerebral organoids - called mini brains - from human embryonic stem cells through a platform called GLICO, which creates genetically matched, patient-specific brain models using an individual's immune cells and glioma cells. These miniature replicas allow researchers to map how a tumor may progress, and test new, individualized therapeutic approaches, offering a hope for transforming glioblastoma into a manageable disease and improving overall survivorship.